Efficacy and safety of more intensive lowering of LDL cholesterol

Lancet. 2011 Feb 26;377(9767):715; author reply 715-6. doi: 10.1016/S0140-6736(11)60261-4.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Age Factors
  • Cholesterol, LDL / blood*
  • Coronary Disease / blood
  • Coronary Disease / prevention & control*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects*
  • Incidence
  • Meta-Analysis as Topic
  • Neoplasms / chemically induced
  • Neoplasms / epidemiology*
  • Neoplasms / etiology*
  • Odds Ratio
  • Pravastatin / administration & dosage
  • Pravastatin / adverse effects*
  • Randomized Controlled Trials as Topic
  • Risk Assessment
  • Risk Factors

Substances

  • Cholesterol, LDL
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Pravastatin